China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
DENVER, April 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Thursday, May 4, 2017 | |
| Time | 9:00 a.m. EDT | |
| Toll free (U.S.) | (888) 372-9592 | |
| Webcast (live and replay) | www.bioscrip.com | |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 8579499.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
